Korea Pharma KRX:032300KOSDAQ
한국파마 · Korean news coverage and regulatory filings, organized.
Articles, 24h0
Articles, 7 days0
DART filings, 7 days0
Articles tracked9since Sep 11
In Q2 2026, Korea Pharma reported revenue of ₩25.9bn, up 10.8% year on year, and operating profit of ₩2.2bn. Korea Pharma (한국파마) appeared in 0 Korean news articles and 0 DART filings over the past seven days.
Filing signals Buyback Screener
Korea Pharma quarterly results separate, KRW
| Quarter | Revenue | YoY | Operating profit | Net income |
|---|---|---|---|---|
| Q2 2026 | ₩25.9bn | +10.8% | ₩2.2bn margin 8.4% | ₩1.3bn |
| Q1 2026 | ₩24.6bn | +18.4% | ₩1.3bn margin 5.3% | ₩682m |
| Q4 2025 derived | ₩19.4bn | -11.4% | −₩2.3bn margin −11.9% | −₩2.8bn |
| Q3 2025 | ₩24.0bn | +24.8% | ₩507m margin 2.1% | −₩21m |
| Q2 2025 | ₩23.4bn | +17.9% | ₩83m margin 0.4% | −₩376m |
| Q1 2025 | ₩20.8bn | +2.5% | ₩831m margin 4.0% | ₩515m |
| Q4 2024 derived | ₩21.9bn | +7.2% | ₩1.9bn margin 8.8% | ₩56m |
| Q3 2024 | ₩19.2bn | -3.0% | ₩1.1bn margin 5.7% | ₩1.3bn |
Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases. Margin is operating profit divided by revenue — see operating margin.
Korea Pharma top stories 2 weeks, by number of outlets
No story covered by multiple outlets in the past two weeks.
Latest Korea Pharma news Korean headlines
-
한국파마, 10억원 규모 자사주 취득…일부 소각·스톡옵션 활용
2 more on this story · 2 outlets
- 한국파마, 10억원 규모 자사주 취득 결정컨슈머타임스 · Oct 2 13:53
- 한국파마, 10억원 규모 자사주 취득 결정뉴스핌 · Oct 2 14:08
-
한국파마, 아동 ADHD 치료기 비급여 목록 등재
1 more on this story · 1 outlets
- 한국파마 '스타러커스', 비급여 목록 등재...아동 ADHD 처방 기반 확대파이낸셜뉴스 · Sep 29 11:54